TRCT
LCTX icon

Tower Research Capital (TRC)’s Lineage Cell Therapeutics LCTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.6K Buy
23,187
+3,716
+19% +$6.27K ﹤0.01% 3011
2025
Q4 		$32.5K Buy
19,471
+15,919
+448% +$27.6K ﹤0.01% 2748
2025
Q3 		$6K Sell
3,552
-23,986
-87% -$28.4K ﹤0.01% 4185
2025
Q2 		$25K Buy
27,538
+4,232
+18% +$2.51K ﹤0.01% 3538
2025
Q1 		$10.5K Sell
23,306
-1,624
-7% -$952 ﹤0.01% 3629
2024
Q4 		$12.5K Buy
24,930
+12,540
+101% +$9.21K ﹤0.01% 3610
2024
Q3 		$11.2K Sell
12,390
-18,787
-60% -$17.4K ﹤0.01% 3681
2024
Q2 		$31.1K Buy
31,177
+30,205
+3,108% +$33.4K ﹤0.01% 3461
2024
Q1 		$1.44K Sell
972
-7,335
-88% -$8.32K ﹤0.01% 5265
2023
Q4 		$9.05K Sell
8,307
-2,030
-20% -$2.22K ﹤0.01% 4442
2023
Q3 		$12.2K Buy
10,337
+2,361
+30% +$3.21K ﹤0.01% 3919
2023
Q2 		$11.2K Sell
7,976
-1,992
-20% -$2.75K ﹤0.01% 3999
2023
Q1 		$15K Sell
9,968
-1,376
-12% -$1.92K ﹤0.01% 3794
2022
Q4 		$13K Buy
11,344
+11,042
+3,656% +$13.9K ﹤0.01% 3617
2022
Q3 		$0 Buy
302
+100
+50% +$147 ﹤0.01% 6305
2022
Q2 		$0 Sell
202
-7,689
-97% -$10.1K ﹤0.01% 6325
2022
Q1 		$12K Buy
7,891
+83
+1% +$129 ﹤0.01% 4068
2021
Q4 		$19K Buy
7,808
+4,161
+114% +$9.74K ﹤0.01% 3727
2021
Q3 		$9K Sell
3,647
-4,968
-58% -$12.7K ﹤0.01% 4448
2021
Q2 		$25K Buy
8,615
+8,415
+4,208% +$21.8K ﹤0.01% 3679
2021
Q1 		$0 Buy
+200
New +$480 ﹤0.01% 5567
2020
Q4 		– Sell
-15,325
Closed -$14K – 5291
2020
Q3 		$14K Sell
15,325
-25,924
-63% -$22.9K ﹤0.01% 3965
2020
Q2 		$36K Buy
+41,249
New +$36.3K ﹤0.01% 3307
2019
Q1 		– Sell
-22,789
Closed -$21K – 4063
2018
Q4 		$21K Buy
22,789
+22,755
+66,926% +$34.9K ﹤0.01% 1902
2018
Q3 		$0 Sell
34
-21,934
-100% -$46.1K ﹤0.01% 4029
2018
Q2 		$39K Buy
+21,968
New +$44.2K ﹤0.01% 1995
2018
Q1 		– Sell
-6,274
Closed -$12K – 3576
2017
Q4 		$12K Sell
6,274
-4,042
-39% -$8.83K ﹤0.01% 2439
2017
Q3 		$26K Buy
+10,316
New +$25.6K ﹤0.01% 2551
2017
Q2 		– Sell
-23
Closed – – 3116
2017
Q1 		$0 Sell
23
-2,450
-99% -$6.96K ﹤0.01% 3524
2016
Q4 		$8K Buy
+2,473
New +$7.59K ﹤0.01% 2777
2015
Q3 		– Sell
-6,766
Closed -$20K – 4421
2015
Q2 		$20K Buy
6,766
+6,726
+16,815% +$26.1K ﹤0.01% 2101
2015
Q1 		$0 Buy
+40
New +$138 ﹤0.01% 4689
2014
Q4 		– Sell
-9,552
Closed -$24K – 4366
2014
Q3 		$24K Buy
9,552
+7,257
+316% +$17.5K ﹤0.01% 2153
2014
Q2 		$6K Sell
2,295
-542
-19% -$1.22K ﹤0.01% 2723
2014
Q1 		$8K Buy
+2,837
New +$8.35K ﹤0.01% 2829

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s LCTX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Lineage Cell Therapeutics (LCTX) stake by 19% in Q1 2026, buying an estimated $6.27K and bringing the position to 23,187 shares worth $36.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3011.

Tower Research Capital (TRC) first reported a position in LCTX in Q1 2014 and has held it in 35 quarters since. The position peaked at $39K in Q2 2018. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Tower Research Capital (TRC) held 23,187 shares of Lineage Cell Therapeutics worth $36.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,716 Lineage Cell Therapeutics shares in Q1 2026, an estimated $6.27K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3011 holding.
  • Tower Research Capital (TRC) first reported a position in Lineage Cell Therapeutics in Q1 2014 and has held it in 35 quarters since.
  • Tower Research Capital (TRC)'s Lineage Cell Therapeutics position peaked at $39K in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.